Integrating Donor-Derived Cell-Free DNA in Your Transplant Monitoring Toolkit
SESSION OVERVIEW: Learn about newly introduced, novel transplant rejection assessment test that noninvasively evaluates donor-derived cell-free DNA to determine risk of rejection of a transplanted kidney. This presentation will cover the basics of integrating values such as absolute quantity of donor-derived cell-free DNA, donor fraction and total cfDNA into your practice to better and more consistently monitor potentially non-compliant adolescents to best protect the donated kidney.
Speakers:
Dr. Sara Jandeska, MD
Dr. Hossein Tabriziani
The Future is Now: Non-Invasive Pediatric Molecular Transplant Testing
SESSION OVERVIEW: Join a panel of experts to discuss the latest advances in molecular diagnostics for pediatric transplant recipients. Moderated by Dr. Vikas Dharnidarka and Dr. Sham Dholakia, and featuring presentations by Dr. Vikas Dharnidharka, Director of Pediatric Nephrology at Washington University in St. Louis, Dr. Dechu Puliyanda, Director of Pediatric Nephrology and Transplant Immunology at the Cedars-Sinai Medical Center in Los Angeles, and Dr. Brian Feingold, Medical Director of Heart Failure and Transplantation Programs at the UPMC Children’s Hospital in Pittsburgh, this symposium will provide an overview of AlloSure donor-derived cell-free DNA (dd-cfDNA), presentations of recently published data on the use of AlloSure in pediatric heart and kidney transplant recipients, and a live Q&A with the speakers.
Speakers:
Dr. Vikas Dharnidharka, MD, MPH
Dr. Dechu Puliyanda, MD
Dr. Brian Feingold, MD, MS, FAHA
Moderators:
Dr. Sham Dholakia, MD, DPhil
Dr. Vikas Dharnidharka, MD, MPH
Immunoadsorption for ABO-incompatible Heart Transplantation
SESSION OVERVIEW: Intraoperative anti-A/B immunoadsorption (ABO-IA) was introduced for ABO-incompatible heart transplantation at Great Ormond Street Hospital for Children (GOSH) in 2015. Since then several patients have undergone ABOi transplantation at GOSH and at other centres around Europe using the technique. Here we discuss the ex-vivo model used to create the methodology, as well as the first case series of patients transplanted with ABO-IA undertaken at GOSH, comparing outcomes with those undergoing plasma exchange facilitated ABO-incompatible heart transplantation (ABO-PE). Finally, a case study will be used to illustrate how intraoperative anti-A/B immunoadsorption is pushing the boundaries of who can be treated with ABOi transplantation.
Speaker:
Dr. Richard Issitt B.Sc(Hons), PgDip, DClinP, FCCP, AACP
Moderator:
